T-CURX Announces $20M Series A Financing

The round was led by BiomedVC, with additional investments from Bayern Kapital, HighLight Capital (HLC), and i&iBio Fund, along with existing and new individual investors.

The company plans to use the funds to accelerate the clinical development of its non-viral CAR-T therapies for AML and solid tumor indications, as well as to advance its proprietary non-viral technologies for in vivo CAR-T generation.

Spun out from the University Clinics Würzburg, T-Curx is led by CEO Ulf Grawunder, PhD, and Prof. Michael Hudecek. The company aims to bring next-generation CAR-T cell therapies, manufactured with non-viral CAR-T cell technologies, to patients in need of effective cancer therapies.

Read Also - Netherlands-based Gambit Cyber Secures $3.4M In Seed Funding

T-Curx utilizes a portfolio of proprietary non-viral CAR-T technologies for scalable and cost-effective CAR-T manufacturing, based on virus-free, Sleeping-beauty transposon gene transfer into patients' T cells.

Ulf Grawunder, PhD, co-founder and CEO of T-CURX, commented on the closing of this Series A financing round for T-CURX:

“I am very excited that T-CURX attracted such a high-profile, international investor’s syndicate, led by BiomedVC, for financing T-CURX`s non-clinical and clinical CAR-T technologies and CAR-T pipeline programs, respectively. It is a testament of the high quality of T-CURX data and the promise of our non-clinical and clinical non-viral CAR-T pipeline in AML & CLL and solid tumor indications going after novel targets.

It also highlights the high value of our unique approach to leverage non-viral CAR-vector and LNP technologies for highly economical and scalable in vivo CAR-T generation, in order to “democratize” CAR-T therapies for patients globally.”

About T-CURX

T-CURX is a privately owned, German biotech company based in Würzburg, founded in 2017. The company was spun out of the laboratory of T-CURX co-founder Prof. Michael Hudecek at the University of Würzburg. It is led by CEO Ulf Grawunder, PhD, a seasoned serial entrepreneur and co-founder. T-CURX focuses on bringing next-generation CAR-T cell therapies to cancer patients using cost-effective and highly scalable non-viral CAR-T cell technologies. The company leverages proprietary non-viral CAR-T technologies for scalable and cost-effective CAR-T manufacturing, based on virus-free, Sleeping-beauty transposon gene transfer into patient’s T cells.